<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31894">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02059018</url>
  </required_header>
  <id_info>
    <org_study_id>HypNOCOX-2</org_study_id>
    <secondary_id>1-10-72-14-14</secondary_id>
    <nct_id>NCT02059018</nct_id>
  </id_info>
  <brief_title>The Mechanisms of Diameter Changes in Retinal Vessels During Hypoxia</brief_title>
  <official_title>The Underlying Mechanisms of Diameter Changes in Retinal Vessels During Hypoxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to study if a stimulation of nitric oxide and/or prostaglandin
      affect the diameter changes of retinal vessels during hypoxia. Diameter changes are studied
      using the Dynamic Vessel Analyzer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Diameter changes of retinal vessels</measure>
    <time_frame>Examination day 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparing the differences of diameter changes occuring during each of interventions</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Retinal Hypoxia</condition>
  <arm_group>
    <arm_group_label>Hypoxia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaling hypoxic gas mixture to induce hypoxemia during recordings of diameter changes of retinal vessels. Recording are performed during hypoxia alone and in combination with the associated interventions over two examination days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normoxia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breathing atmospheric air during recordings of diameter changes of retinal vessels. Recording are performed during normoxia alone and in combination with the associated interventions over two examination days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COX-inhibitor</intervention_name>
    <description>Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated</description>
    <arm_group_label>Hypoxia</arm_group_label>
    <arm_group_label>Normoxia</arm_group_label>
    <other_name>Eye drops diclofenac 1mg/ml</other_name>
    <other_name>Voltaren eye drops</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin</intervention_name>
    <description>Oral administration of tablet nitroglycerin 0,5mg 5 minutes before recordings of diameter changes of retinal vessels are initiated</description>
    <arm_group_label>Hypoxia</arm_group_label>
    <arm_group_label>Normoxia</arm_group_label>
    <other_name>Glyceryl Nitrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COX-inhibitor + Nitroglycerin</intervention_name>
    <description>Combination of COX-inhibitor and nitroglycerin interventions.</description>
    <arm_group_label>Hypoxia</arm_group_label>
    <arm_group_label>Normoxia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between &gt;19 and &lt;61 years

          -  No known systemic or ocular diseases

        Exclusion Criteria:

          -  Cardio-vascular disease

          -  Lung disease

          -  Epilepsy

          -  Previous ocular disease

          -  Previous treatment with medications influencing the intraocular pressure or the
             metabolism of nitric oxide or prostaglandins

          -  Daily intake of medicine except contraceptive pills

          -  Pregnancy or breastfeeding

          -  Known allergy against any of the drugs used in the interventions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Line Pedersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Musa Kaya, stud.med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Line Pedersen, MD</last_name>
    <phone>+4578463250</phone>
    <email>linperse@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Musa Kaya, stud.med</last_name>
    <phone>+4560294764</phone>
    <email>musa_kaya@studmed.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Ophtalmology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>February 10, 2014</lastchanged_date>
  <firstreceived_date>February 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Cyclooxygenase Inhibitors</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
